Abstract | BACKGROUND AND PURPOSE: Preclinical and retrospective clinical data indicate that glyburide, a selective inhibitor of sulfonylurea receptor 1-transient receptor potential melastatin 4, is effective in preventing edema and improving outcome after focal ischemia. We assessed the feasibility of recruiting and treating patients with severe stroke while obtaining preliminary information on the safety and tolerability of RP-1127 ( glyburide for injection). METHODS: RESULTS: Recruitment was completed within 10 months. The mean age was 50.5 years, and baseline diffusion-weighted image lesion volume was 102±23 cm3. There were no serious adverse events related to drug and no symptomatic hypoglycemia. The increase in ipsilateral hemisphere volume was 50±33 cm3. The proportion of 90-day modified Rankin Scale≤4 was 90% (40% modified Rankin Scale, ≤3). CONCLUSIONS: RP-1127 at a dose of 3 mg/d was well tolerated and did not require any dose reductions. A clinical trial of RP-1127 is feasible. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01268683.
|
Authors | Kevin N Sheth, W Taylor Kimberly, Jordan J Elm, Thomas A Kent, Pitchaiah Mandava, Albert J Yoo, Götz Thomalla, Bruce Campbell, Geoffrey A Donnan, Stephen M Davis, Gregory W Albers, Sven Jacobson, J Marc Simard, Barney J Stern |
Journal | Stroke
(Stroke)
Vol. 45
Issue 1
Pg. 281-3
(Jan 2014)
ISSN: 1524-4628 [Electronic] United States |
PMID | 24193798
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Blood Glucose
- Fibrinolytic Agents
- Hypoglycemic Agents
- Tissue Plasminogen Activator
- Glyburide
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Blood Glucose
(metabolism)
- Brain Edema
(drug therapy, etiology)
- Brain Ischemia
(drug therapy)
- Comorbidity
- Female
- Fibrinolytic Agents
(therapeutic use)
- Glyburide
(administration & dosage, adverse effects, therapeutic use)
- Humans
- Hypoglycemia
(chemically induced)
- Hypoglycemic Agents
(administration & dosage, adverse effects, therapeutic use)
- Injections, Intravenous
- Magnetic Resonance Imaging
- Male
- Middle Aged
- Patient Safety
- Pilot Projects
- Prospective Studies
- Stroke
(drug therapy)
- Tissue Plasminogen Activator
(therapeutic use)
- Treatment Outcome
- White People
- Young Adult
|